Evofem Biosciences, Inc. CEO Saundra Pelletier Discusses Why $EVFM is a Company to Watch

Digital Asset Direct by Benzinga

Detroit, MI | August 01, 2022 09:47 AM Eastern Daylight Time

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a biopharmaceutical company developing & commercializing products to address needs in women's sexual & reproductive health. The Company's 1st FDA-approved product, Phexxi® (lactic acid, citric acid & potassium bitartrate), is a hormone-free prescription contraceptive vaginal gel. The Company may report top-line data in fall 2022 from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for 2 potential new indications – prevention of chlamydia & of gonorrhea in women. Visit phexxi.com & evofem.com.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com